Effect of severe renal impairment on pharmacokinetics, safety, and tolerability of lemborexant

The primary aim of this study was to examine the effect of severe renal impairment (SRI) on the pharmacokinetics of lemborexant, a dual orexin receptor antagonist indicated for the treatment of insomnia. A phase 1 multicenter, single‐dose, open‐label, parallel‐group study was conducted in subjects w...

Descripción completa

Detalles Bibliográficos
Autores principales: Landry, Ishani, Aluri, Jagadeesh, Hall, Nancy, Filippov, Gleb, Dayal, Satish, Moline, Margaret, Reyderman, Larisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7945683/
https://www.ncbi.nlm.nih.gov/pubmed/33689224
http://dx.doi.org/10.1002/prp2.734

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7945683/
https://www.ncbi.nlm.nih.gov/pubmed/33689224
http://dx.doi.org/10.1002/prp2.734

Ejemplares similares